Elsevier

Gynecologic Oncology

Volume 45, Issue 3, June 1992, Pages 284-289
Gynecologic Oncology

Regular article
Randomized prospective trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin, and cisplatin in advanced ovarian carcinoma

https://doi.org/10.1016/0090-8258(92)90305-3Get rights and content

Abstract

Five versus ten cycles of cyclophosphamide, doxorubicin, and cisplatin (CAP) were compared in advanced ovarian carcinoma by a prospective randomized study of 78 patients, 41 receiving 5 cycles (CAPS) and 37 receiving 10 cycles (CAP10) of chemotherapy. Patients were stratified by histologic grade and size of residual disease. Cyclophosphamide, 600 mg/m2, doxorubicin, 40 mg/m2, and cisplatin, 100 mg/m2, were administered every 4 weeks for 5 or 10 cycles. Second-look laparotomy was performed to evaluate response and plan further therapy. CAPS patients found at second-look laparotomy to have partially responded to chemotherapy were treated with 5 additional cycles of CAP. CAP10 was more toxic than CAPS with respect to myelosuppression, hospital admissions for nadir fever, median elevation of creatinine, and degree of peripheral neuropathy. Median follow-up is 64 months. CAPS and CAP10 were equivalent in surgically documented complete responses (34 versus 35%) and survival (P = 0.41). Twelve partial responders to CAPS received additional CAP chemotherapy; one complete response resulted. We conclude that CAP5 is preferable to CAP10 in treatment of advanced ovarian cancer as it is equally effective and less toxic.

References (20)

  • Unpublished...
  • P.J. Stiff et al.

    Prolonged combination chemotherapy for ovarian carcinoma does not increase the rate of surgical complete remission

  • F.A. Greco et al.

    Advanced ovarian cancer: Brief intensive combination chemotherapy and second-look operation

    Obstet. Gynecol.

    (1981)
  • J.P. Neijt et al.

    Randomized trial comparing two combination chemotherapy regimens (CAP-5 v CP) in advanced ovarian carcinoma

    J. Clin. Oncol.

    (1987)
  • G.A. Omura et al.

    Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group study

    J. Clin. Oncol.

    (1989)
  • Randomized comparison of cisplatin with cyclophosphamide/cisplatin and with cyclophosphamide/doxorubicin/cisplatin in advanced ovarian cancer

    Lancet

    (1987)
  • E.L. Kaplan et al.

    Nonparametric estimation from incomplete observations

    J. Am. Stat. Assoc.

    (1958)
  • J.H. Zar
  • K. Bertelsen et al.

    A randomized trial of six versus twelve cycles of cyclophosphamide, adriamycin in advanced ovarian cancer

  • A. Jakobsen et al.

    Long-term versus short-term chemotherapy in advanced ovarian cancer

There are more references available in the full text version of this article.

Cited by (153)

  • Does adjuvant chemotherapy dose modification have an impact on the outcome of patients diagnosed with advanced stage ovarian cancer? An NRG Oncology/Gynecologic Oncology Group study

    2018, Gynecologic Oncology
    Citation Excerpt :

    Increasing the number of cycles or the dose of chemotherapy per cycle has not resulted in any significant therapeutic advantage in terms of progression-free survival (PFS) or OS [5]. It has been previously shown that similar outcomes were seen in patients treated with 5 versus 12 cycles of chemotherapy [6–9]. Nonetheless, there are reasons to believe that completing the number of prescribed chemotherapy cycles on schedule without dose reduction may be associated with improved clinical outcomes.

  • Epithelial ovarian cancer

    2018, Clinical Gynecologic Oncology
  • Neoadjuvant chemotherapy and chemotherapy cycle number: A national multicentre study

    2017, Gynecologic Oncology
    Citation Excerpt :

    Hakes et al. (1992) first performed a prospective randomized control trial of 5 versus 10 cycles of cyclophosphamide, doxorubicin and cisplatin (CAP) every 4 weeks. The authors found no difference in OS or CCR rate [24]. Bertelsen et al. (1993) examined 202 patients with 6 versus 12 cycles of CAP, and also found no difference in OS [25].

  • Long-term results of a randomised phase III trial of weekly versus three-weekly paclitaxel/platinum induction therapy followed by standard or extended three-weekly paclitaxel/platinum in European patients with advanced epithelial ovarian cancer

    2014, European Journal of Cancer
    Citation Excerpt :

    Previous studies have shown conflicting results of prolonging chemotherapy in first-line EOC beyond six cycles. Two prior studies showed no benefit, confirming our results, and in one study median PFS was improved without improvement in OS and at the cost of increased toxicity [23–25]. Ethnicity may partly explain the different outcomes of the above-mentioned clinical trials.

View all citing articles on Scopus

Supported in part by the Avon Program for Ovarian Cancer and NCI CA5826-23.

View full text